Insights into Overlappings of Fibrosis and Cancer: Exploring the Tumor-related Cardinal Genes in Idiopathic Pulmonary Fibrosis
Abstract
The pathogenesis of idiopathic pulmonary fibrosis (IPF) is quite similar to that of cancer pathogenesis, and several pathways appear to be involved in both disorders. The mammalian target of the rapamycin (mTOR) pathway harbors several established oncogenes and tumor suppressors. The same signaling molecules and growth factors, such as vascular endothelial growth factor (VEGF), contributing to cancer development and progression play a part in fibroblast proliferation, myofibroblast differentiation, and the production of extracellular matrix in IPF development as well.
The expression of candidate genes acting upstream and downstream of mTORC1, as well as Vegf and low-density lipoprotein receptor related protein 1(Lrp1), was assessed using specific primers and quantitative polymerase chain reaction (qPCR) within the lung tissues of bleomycin (BLM)-induced IPF mouse models. Lung fibrosis was evaluated by histological examinations and hydroxyproline colorimetric assay.
BLM-exposed mice developed lung injuries characterized by inflammatory manifestations and fibrotic features, along with higher levels of collagen and hydroxyproline. Gene expression analyses indicated a significant elevation of regulatory associated protein of mTOR (Raptor), Ras homolog enriched in brain (Rheb), S6 kinase 1, and Eukaryotic translation initiation factor 4E-binding protein 1 (4Ebp1), as well as a significant reduction of Vegfa, Tuberous sclerosis complex (Tsc2), and Lrp1; no changes were observed in the Tsc1 mRNA level.
Our findings support the elevation of S6K1 and 4EBP1 in response to the TSC/RHEB/mTORC1 axis, which profoundly encourages the development and establishment of IPF and cancer. In addition, this study suggests a possible preventive role for VEGF-A and LRP1 in the development of IPF.
2. Carrington R, Jordan S, Pitchford S, Page C. Use of animal models in IPF research. Pulmonary pharmacology & therapeutics. 2018;51:73-8.
3. Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Annals of internal medicine. 2001;134(2):136-51.
4. Vancheri C. Common pathways in idiopathic pulmonary fibrosis and cancer. European respiratory review: an official journal of the European Respiratory Society. 2013;22(129):265-72.
5. Dempsey OJ. Clinical review: idiopathic pulmonary fibrosis--past, present and future. Respiratory medicine. 2006;100(11):1871-85.
6. Cox TR, Erler JT. Molecular pathways: connecting fibrosis and solid tumor metastasis. Clinical Cancer Research. 2014;20(14):3637-43.
7. Stella GM, Inghilleri S, Pignochino Y, Zorzetto M, Oggionni T, Morbini P, et al. Activation of oncogenic pathways in idiopathic pulmonary fibrosis. Translational oncology. 2014;7(5):650-5.
8. Leng D, Yi J, Xiang M, Zhao H, Zhang Y. Identification of common signatures in idiopathic pulmonary fibrosis and lung cancer using gene expression modeling. BMC cancer. 2020;20(1):1-15.
9. Hassan B, Akcakanat A, Holder AM, Meric-Bernstam F. Targeting the PI3-kinase/Akt/mTOR signaling pathway. Surgical Oncology Clinics. 2013;22(4):641-64.
10. Ma L, Teruya-Feldstein J, Bonner P, Bernardi R, Franz DN, Witte D, et al. Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase–mediated mTOR activation in tuberous sclerosis and human cancer. Cancer research. 2007;67(15):7106-12.
11. Inoki K, Li Y, Xu T, Guan K-L. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes & development. 2003;17(15):1829-34.
12. Lawrence J, Nho R. The Role of the Mammalian Target of Rapamycin (mTOR) in Pulmonary Fibrosis. International journal of molecular sciences. 2018;19(3).
13. Bayati P, Taherian M, Assarehzadegan MA, Soleimani M, Poormoghim H, Mojtabavi N. Induced Pluripotent Stem-cells Inhibit Experimental Bleomycin-induced Pulmonary Fibrosis through Regulation of the Insulin-like Growth Factor Signaling. Iran J Allergy Asthma Immunol. 2022;21(3):263-72.
14. Yang Y, Cao Y, editors. The impact of VEGF on cancer metastasis and systemic disease. Seminars in Cancer Biology; 2022: Elsevier.
15. Amano H, Matsui Y, Hatanaka K, Hosono K, Ito Y. VEGFR1-tyrosine kinase signaling in pulmonary fibrosis. Inflammation and regeneration. 2021;41(1):1-8.
16. Xing P, Liao Z, Ren Z, Zhao J, Song F, Wang G, et al. Roles of low-density lipoprotein receptor-related protein 1 in tumors. Chinese journal of cancer. 2016;35(1):1-8.
17. Nichols CE, House JS, Li H, Ward JM, Wyss A, Williams JG, et al. Lrp1 regulation of pulmonary function. Follow-up of human GWAS in mice. American journal of respiratory cell and molecular biology. 2021;64(3):368-78.
18. Adamson IY, Bowden DH. The pathogenesis of bleomycin-induced pulmonary fibrosis in mice. Am J Pathol. 1974;77(2):185-97.
19. Stegemann H, Stalder K. Determination of hydroxyproline. Clinica chimica acta; international journal of clinical chemistry. 1967;18(2):267-73.
20. Moeller A, Ask K, Warburton D, Gauldie J, Kolb M. The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? The international journal of biochemistry & cell biology. 2008;40(3):362-82.
21. Mehdizadeh S, Taherian M, Bayati P, Mousavizadeh K, Pashangzadeh S, Anisian A, et al. Plumbagin attenuates Bleomycin-induced lung fibrosis in mice. Allergy, Asthma & Clinical Immunology. 2022;18(1):93.
22. Hasbani DM, Crino PB. Tuberous sclerosis complex. Handbook of clinical neurology. 2018;148:813-22.
23. Wang Y, Chen C, Deng Z, Bian E, Huang C, Lei T, et al. Repression of TSC1/TSC2 mediated by MeCP2 regulates human embryo lung fibroblast cell differentiation and proliferation. International journal of biological macromolecules. 2017;96:578-88.
24. Jiang L, Xu L, Mao J, Li J, Fang L, Zhou Y, et al. Rheb/mTORC1 signaling promotes kidney fibroblast activation and fibrosis. Journal of the American Society of Nephrology. 2013;24(7):1114-26.
25. Xiao L, Wang YC, Li WS, Du Y. The role of mTOR and phospho-p70S6K in pathogenesis and progression of gastric carcinomas: an immunohistochemical study on tissue microarray. Journal of experimental & clinical cancer research : CR. 2009;28(1):152.
26. Segatto I, Berton S, Sonego M, Massarut S, Fabris L, Armenia J, et al. p70S6 kinase mediates breast cancer cell survival in response to surgical wound fluid stimulation. Molecular oncology. 2014;8(3):766-80.
27. Klos KS, Wyszomierski SL, Sun M, Tan M, Zhou X, Li P, et al. ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells. Cancer research. 2006;66(4):2028-37.
28. Kwon HK, Bae GU, Yoon JW, Kim YK, Lee HY, Lee HW, et al. Constitutive activation of p70S6k in cancer cells. Archives of pharmacal research. 2002;25(5):685-90.
29. Silvera D, Formenti SC, Schneider RJ. Translational control in cancer. Nature reviews Cancer. 2010;10(4):254-66.
30. Karlsson E, Pérez-Tenorio G, Amin R, Bostner J, Skoog L, Fornander T, et al. The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials. Breast cancer research : BCR. 2013;15(5):R96.
31. Loibl S, Darb-Esfahani S, Huober J, Klimowicz A, Furlanetto J, Lederer B, et al. Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016;22(11):2675-83.
32. Braunstein S, Karpisheva K, Pola C, Goldberg J, Hochman T, Yee H, et al. A hypoxia-controlled cap-dependent to cap-independent translation switch in breast cancer. Molecular cell. 2007;28(3):501-12.
33. Rutkovsky AC, Yeh ES, Guest ST, Findlay VJ, Muise-Helmericks RC, Armeson K, et al. Eukaryotic initiation factor 4E-binding protein as an oncogene in breast cancer. Bmc Cancer. 2019;19(1):1-15.
34. Ando M, Miyazaki E, Ito T, Hiroshige S, Nureki SI, Ueno T, et al. Significance of serum vascular endothelial growth factor level in patients with idiopathic pulmonary fibrosis. Lung. 2010;188(3):247-52.
35. Vij R, Noth I. Peripheral blood biomarkers in idiopathic pulmonary fibrosis. Translational research : the journal of laboratory and clinical medicine. 2012;159(4):218-27.
36. Antoniou KM, Soufla G, Lymbouridou R, Economidou F, Lasithiotaki I, Manousakis M, et al. Expression analysis of angiogenic growth factors and biological axis CXCL12/CXCR4 axis in idiopathic pulmonary fibrosis. Connective tissue research. 2010;51(1):71-80.
37. Malli F, Koutsokera A, Paraskeva E, Zakynthinos E, Papagianni M, Makris D, et al. Endothelial progenitor cells in the pathogenesis of idiopathic pulmonary fibrosis: an evolving concept. PloS one. 2013;8(1):e53658.
38. Inui N, Sakai S, Kitagawa M. Molecular Pathogenesis of Pulmonary Fibrosis, with Focus on Pathways Related to TGF-β and the Ubiquitin-Proteasome Pathway. International Journal of Molecular Sciences. 2021;22(11):6107.
39. Meng H, Chen G, Zhang X, Wang Z, Thomas DG, Giordano TJ, et al. Stromal LRP1 in Lung Adenocarcinoma Predicts Clinical OutcomeLRP1 Suppresses Lung Cancer Cell Growth. Clinical Cancer Research. 2011;17(8):2426-33.
40. Huang X-Y, Shi G-M, Devbhandari RP, Ke A-W, Wang Y, Wang X-Y, et al. Low level of low-density lipoprotein receptor-related protein 1 predicts an unfavorable prognosis of hepatocellular carcinoma after curative resection. PloS one. 2012;7(3):e32775.
41. Catasus L, Gallardo A, Llorente-Cortes V, Escuin D, Muñoz J, Tibau A, et al. Low-density lipoprotein receptor–related protein 1 is associated with proliferation and invasiveness in Her-2/neu and triple-negative breast carcinomas. Human pathology. 2011;42(11):1581-8.
42. Boulagnon-Rombi C, Schneider C, Leandri C, Jeanne A, Grybek V, Bressenot AM, et al. LRP1 expression in colon cancer predicts clinical outcome. Oncotarget. 2018;9(10):8849.
Files | ||
Issue | Vol 22 No 2 (2023) | |
Section | Original Article(s) | |
DOI | https://doi.org/10.18502/ijaai.v22i2.12680 | |
Keywords | ||
Idiopathic pulmonary fibrosis Cancer mTOR Rptor S6k1 4E-bp1 Rheb1 Lrp1 Tsc1 Tsc2 Vegf |
Rights and permissions | |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |